177 related articles for article (PubMed ID: 11196068)
1. Evaluation of a highly specific functional test for the detection of factor V Leiden.
Quenhenberger P; Handler S; Mannhalter C; Pabinger-Fasching I; Speiser W
Int J Clin Lab Res; 2000; 30(3):113-7. PubMed ID: 11196068
[TBL] [Abstract][Full Text] [Related]
2. The Factor V (Leiden) test: evaluation of an assay based on dilute Russell Viper Venom Time for the detection of the Factor V Leiden mutation.
Quehenberger P; Handler S; Mannhalter C; Kyrle PA; Speiser W
Thromb Res; 1999 Oct; 96(2):125-33. PubMed ID: 10574590
[TBL] [Abstract][Full Text] [Related]
3. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
[TBL] [Abstract][Full Text] [Related]
4. Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Reuner KH; Litfin F; Patscheke H
Eur J Clin Chem Clin Biochem; 1997 Jan; 35(1):41-5. PubMed ID: 9156566
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Schöni R; Quehenberger P; Wu JR; Wilmer M
Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
[TBL] [Abstract][Full Text] [Related]
6. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
[TBL] [Abstract][Full Text] [Related]
7. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
8. Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.
Amiral J; Vissac AM; Seghatchian J
Transfus Apher Sci; 2017 Dec; 56(6):906-913. PubMed ID: 29162399
[TBL] [Abstract][Full Text] [Related]
9. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
Kraus M; Zander N; Fickenscher K
Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
[TBL] [Abstract][Full Text] [Related]
10. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
[TBL] [Abstract][Full Text] [Related]
11. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
12. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
13. Assessment of activated protein C resistance using a new and rapid venom-based test: STA Staclot APC-R.
Oger E; Leroyer C; Mercier B; Van Dreden P; Bressollette L; De Saint-Martin L; Le Moigne E; Blouch MT; Thuillier N; Amiral J; Ferec C; Abgrall JF; Mottier D
Blood Coagul Fibrinolysis; 1998 Jun; 9(4):355-9. PubMed ID: 9690807
[TBL] [Abstract][Full Text] [Related]
14. Detecting APC-resistant factor V: a functional method without plasma dilution.
Rylatt DB; Hohnen-Behrens C; Pilgrim RL; Dickeson LE; Neal M; Exner T
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):359-66. PubMed ID: 10493217
[TBL] [Abstract][Full Text] [Related]
15. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
[TBL] [Abstract][Full Text] [Related]
16. An improved test to identify aPC-resistant factor V-Leiden.
Preda L; Erba N; Figini S; Carniti GC; Rossi E
Thromb Res; 1997 Jun; 86(6):461-8. PubMed ID: 9219326
[TBL] [Abstract][Full Text] [Related]
17. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Kabukcu S; Keskin N; Keskin A; Atalay E
Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
[TBL] [Abstract][Full Text] [Related]
18. Careful selection of sample dilution and factor-V-deficient plasma makes the modified activated protein C resistance test highly specific for the factor V Leiden mutation.
de Ronde H; Bertina RM
Blood Coagul Fibrinolysis; 1999 Jan; 10(1):7-17. PubMed ID: 10070830
[TBL] [Abstract][Full Text] [Related]
19. Factor V Leiden, activated protein C resistance, and retinal vein occlusion.
Ciardella AP; Yannuzzi LA; Freund KB; DiMichele D; Nejat M; De Rosa JT; Daly JR; Sisco L
Retina; 1998; 18(4):308-15. PubMed ID: 9730172
[TBL] [Abstract][Full Text] [Related]
20. [Clinical usefulness of global assays of the anticoagulant pathway of protein C].
Toulon P
Ann Biol Clin (Paris); 2001; 59(5):545-50. PubMed ID: 11602384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
